Market closed
TScan Therapeutics/$TCRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Ticker
$TCRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
194
Website
TCRX Metrics
BasicAdvanced
$120M
-
-$2.09
0.78
-
Price and volume
Market cap
$120M
Beta
0.78
52-week high
$9.69
52-week low
$1.99
Average daily volume
356K
Financial strength
Current ratio
9.563
Quick ratio
9.46
Long term debt to equity
37.74
Total debt to equity
39.442
Interest coverage (TTM)
-32.11%
Management effectiveness
Return on assets (TTM)
-23.35%
Return on equity (TTM)
-55.92%
Valuation
Price to revenue (TTM)
12.139
Price to book
0.5
Price to tangible book (TTM)
0.5
Price to free cash flow (TTM)
-1.028
Growth
Revenue change (TTM)
-44.71%
Earnings per share change (TTM)
12.95%
3-year revenue growth (CAGR)
5.02%
3-year earnings per share growth (CAGR)
-33.64%
What the Analysts think about TCRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for TScan Therapeutics stock.
TCRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TCRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TCRX News
AllArticlesVideos
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
GlobeNewsWire·1 week ago
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
Seeking Alpha·2 weeks ago
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for TScan Therapeutics stock?
TScan Therapeutics (TCRX) has a market cap of $120M as of February 26, 2025.
What is the P/E ratio for TScan Therapeutics stock?
The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of February 26, 2025.
Does TScan Therapeutics stock pay dividends?
No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next TScan Therapeutics dividend payment date?
TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for TScan Therapeutics?
TScan Therapeutics (TCRX) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.